As primary melanoma is associated with Th2-mediated chronic inflammation and VEGF overexpression in favor of tumor progression and metastasis (Nevala et al., 2009; Grotz et al., 2015), targeting of both Th2 polarization and VEGF-mediated angiogenesis in early-stage melanoma may constitute a viable therapeutic option. The gene discussed is VEGFA; the disease is neoplasm.